Newer antihypertensive therapy reduces cardiovascular events
نویسندگان
چکیده
منابع مشابه
Optimizing cardiovascular risk reduction during antihypertensive therapy.
Over the past decade, pharmacological treatment of elevated blood pressure has evolved from empiricism to a more individualized approach based on patient characteristics and an expanding understanding of the impact of specific agents on the pathophysiology of hypertension and, more importantly, cardiovascular disease. Although blood pressure elevation has been shown to be a powerful risk factor...
متن کاملBedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.
Time of ingestion of hypertension medications can affect circadian patterns of BP, but whether this translates into an effect on clinical outcomes is unknown. Here, in an open-label trial, we randomly assigned 661 patients with CKD either to take all prescribed hypertension medications upon awakening or to take at least one of them at bedtime. We measured 48-hour ambulatory BP at baseline and 3...
متن کاملIvabradine reduces cardiovascular events in angina patients.
these substudy results in angina patients are concordant with the main findings of the BEAUTIfUL study as announced last year in Munich. ‘The sample size of angina patients in the substudy is relevant and the results are plausible’, he pointed out. The BEAUTIfUL trial (morbidity– mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfuncti...
متن کاملInitial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study.
This study evaluated the effects of initial versus delayed treatment with a drug combination on blood pressure (BP) control and the risk of cardiovascular (CV) events in hypertensive patients. Clinical trials suggest that the time to BP control is an important determinant of long-term outcomes, but real-world evidence is scarce. Using electronic medical charts (2005-2009), we retrospectively an...
متن کاملCANTOS results show anti-inflammatory therapy lowers future cardiovascular events, reduces cancer incidence and mortality
Yesterday’s ESC Hot Line: Late Breaking Clinical Trials I Session marked a historic turning point in cardiology with a host of seminal, practice-changing data being presented. One of the highlights was the landmark CANTOS study that showed reducing inflammation, even in the absence of lipid lowering, significantly reduces recurrent cardiovascular events. Canakinumab, a drug currently indicated ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2005
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.331.7516.533-a